Epidemiologic trends in the utilization, demographics, and cost of bone morphogenetic protein in spinal fusions

Bone morphogenetic protein (BMP) utilization as an adjunct for spinal arthrodesis has gained considerable momentum among spine surgeons. Despite carrying Food and Drug Administration approval for only single level anterior lumbar interbody fusion from L4-S1, the majority of BMP administration is in...

Full description

Saved in:
Bibliographic Details
Published in:Current reviews in musculoskeletal medicine 2014-09, Vol.7 (3), p.177-181
Main Authors: Louie, Philip K., Hassanzadeh, Hamid, Singh, Kern
Format: Article
Language:English
Subjects:
Medicine
Medicine & Public Health
Minimally Invasive Surgery
Orthopedics
Rehabilitation Medicine
Section Editor
Spine: BMP (K Singh
Spine: BMP (K Singh, Section Editor)
Sports Medicine
Surgery
Surgical Orthopedics
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Bone morphogenetic protein (BMP) utilization as an adjunct for spinal arthrodesis has gained considerable momentum among spine surgeons. Despite carrying Food and Drug Administration approval for only single level anterior lumbar interbody fusion from L4-S1, the majority of BMP administration is in “off label” settings. Over the last decade, BMP utilization has increased in all facets of spine surgery with the only exception being the anterior cervical spine, in which a downward trend resulted following the 2008 Food and Drug Administration warnings. The future application of BMP in spinal fusion, especially in anterior cervical fusions, will need to be further clarified in terms of efficacy, complications, and cost-effectiveness.
ISSN:1935-973X
1935-9748
DOI:10.1007/s12178-014-9222-2